NIH contract
Indee Labs Nets $2M From NCI to Scale Up Cell Therapy Development, Manufacturing Platform
The firm will put the funds toward evaluating whether its Hydropore platform can generate cell therapies with improved function and efficacy in vivo.
The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.